...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: No mention of efficacy again...

The "problem" here is that no one knows how Vascepa works. So no one would know whether or not they'd be complementary until a specific Phase 3 were to be run, right?

Anyway, it seems to me that A is more a threat to V than the other way around. If that's the case, the owners of AMRN stock should be concerned....

 

 

Share
New Message
Please login to post a reply